Rabies Infection Pipeline Analysis Report 2025

Rabies is a major public health concern in more than 150 nations and territories, primarily in Asia and Africa. Tens of thousands of people die each year from this neglected tropical disease, which is zoonotic and viral. Of those, 40% are youngsters under the age of 15. Patients typically range in age from 5-14. An estimated 59,000 people die from rabies each year worldwide. The rabies infection pipeline analysis by the publisher focuses on various treatment options for this disease. Recent developments include Freeze-dried human rabies vaccine, purified vero rabies vaccine and others. Increasing research, improved diagnostics, and innovative treatments are expected to fuel the growth of rabies infection drug candidates in the coming years.

Report Coverage

The Rabies Infection Pipeline Analysis Report by the publisher gives comprehensive insights into rabies infection therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Rabies Infection therapeutics. The rabies infection report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The rabies infection pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with rabies infection treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to rabies infection.

Rabies Infection Pipeline Outlook

Usually spread by an infected animal's bite or scratch, rabies is a fatal virus that damages the central nervous system. Once symptoms start to show, the infection spreads quickly and, if left untreated, almost usually results in death. Ongoing research and development of vaccinations, monoclonal antibodies, and antiviral treatments to enhance preventive and post-exposure care are all part of the pipeline for rabies infection. Additionally, efforts are made to improve immune response and vaccination accessibility, particularly in endemic areas.

The central nervous system is impacted by the potentially lethal viral infection known as rabies, which is nearly invariably fatal once symptoms start to show. The key to prevention is timely post-exposure prophylaxis (PEP), which consists of immunization, rabies immunoglobulin, and wound care. With continuous improvements aimed at enhancing accessibility and dosing schedules, the current vaccines, which were created utilizing cell culture technologies, are safe and efficacious. Traditional rabies immunoglobulin is being replaced by monoclonal antibody treatments. To improve stability and delivery in endemic areas and aid in the worldwide drive to eradicate rabies, companies such as Yisheng Biopharma have been creating next-generation rabies vaccines in recent years, including freeze-dried formulations.

Rabies Infection Epidemiology

With an almost 100% fatality rate, rabies is currently the most deadly and widespread infectious illness in the world. It results in about 59,000 fatalities and more than 3.7 million disability adjusted life years (DALYs) lost each year. Vaccination can prevent rabies. India is responsible for 35% of rabies deaths worldwide and 59.9% of deaths in Asia.

Rabies Infection - Pipeline Therapeutic Assessment

This section of the report covers the analysis of rabies infection drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Peptides
• Polymers
• Monoclonal Antibodies
• Gene Therapy

By Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Rabies Infection - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total rabies infection clinical trials.

In the rabies infection pipeline, most candidates are in Phase II with 20% of the projects and 80% are in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.

Rabies Infection - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the rabies infection pipeline analysis include small molecules, monoclonal antibody, peptides, polymer, and gene therapy. The rabies infection report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for rabies infection.

Cadila Pharmaceuticals introduced ThRabis, the first three-dose rabies vaccine based on recombinant nanoparticles, in April 2022. In contrast to the conventional five-dose schedule spread over 28 days, ThRabis streamlines the vaccination schedule to three doses spread over one week, which may increase patient compliance and lower the number of rabies-related deaths. ThRabis was honored with the "Pharma Innovation of the Year Award" at the India Pharma World Awards in December 2023 for its innovative role in preventing rabies.

Rabies Infection Clinical Trials - Key Players

The report for the rabies infection pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in rabies infection clinical trials:

• Yisheng Biopharma (Singapore) Pte. Ltd.
• Ningbo Rongan Biological Pharmaceutical Co., Ltd.
• Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
• Sanofi Pasteur, a Sanofi Company
• Changchun BCHT Biotechnology Co.

Rabies Infection - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Rabies Infection. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of rabies infection drug candidates.

Drug: Chirorab

Yisheng Biopharma (Singapore) Pte. Ltd. created the rabies vaccine Chirorab, which is intended to prevent rabies infection both before and after exposure. It is a pure inactivated vaccination that boosts the production of neutralizing antibodies against the rabies virus by the body's immune system. Chirorab can be administered intramuscularly or intradermally and is made in accordance with WHO guidelines for rabies vaccination. The vaccine is a component of continuous initiatives to increase access to reasonably priced and efficient rabies prevention, especially in areas where the disease is endemic. Numerous national vaccination programs already employ it, and its safety and immunogenicity are continuously assessed.

Biological: Freeze-Dried Human Rabies Vaccine (Vero Cells) Chengda

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. created the freeze-dried Human Rabies Vaccine (Vero Cells) Chengda, a purified, inactivated vaccine intended to prevent human rabies. This vaccine, which is made with Vero cell culture technique, functions by inducing the production of neutralizing antibodies against the rabies virus by the immune system. It meets WHO guidelines for rabies vaccination and can be used for both pre-exposure and post-exposure prophylaxis. It is perfect for distribution in rabies-endemic areas because of its freeze-dried formulation, which improves stability and shelf life. National immunization programs use the vaccine, which is still being studied for immunogenicity, safety, and effectiveness.

Key Questions Answered in the Rabies Infection Pipeline Analysis Report

• Which companies/institutions are leading the rabies infection drug development?
• What is the efficacy and safety profile of rabies infection pipeline drugs?
• Which company is leading the rabies infection pipeline development activities?
• What is the current rabies infection commercial assessment?
• What are the opportunities and challenges present in the rabies infection pipeline landscape?
• What is the efficacy and safety profile of rabies infection pipeline drugs?
• Which company is conducting major trials for rabies infection drugs?
• Which companies/institutions are involved in rabies infection collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in rabies infection?

This product will be delivered within 3-5 business days.